Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. / Magnusson, Cecilia; Mezhybovska, Maryna; Lörinc, Ester; Fernebro, Eva; Nilbert, Mef; Sjölander, Anita; Magnusson, Cecilia; Mezhybovska, Maryna; Lörinc, Ester; Fernebro, Eva; Nilbert, Mef; Sjölander, Anita.

In: European Journal of Cancer, Vol. 46, No. 4, 2010, p. 826-35.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Magnusson, C, Mezhybovska, M, Lörinc, E, Fernebro, E, Nilbert, M, Sjölander, A, Magnusson, C, Mezhybovska, M, Lörinc, E, Fernebro, E, Nilbert, M & Sjölander, A 2010, 'Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer', European Journal of Cancer, vol. 46, no. 4, pp. 826-35. https://doi.org/10.1016/j.ejca.2009.12.022, https://doi.org/10.1016/j.ejca.2009.12.022

APA

Magnusson, C., Mezhybovska, M., Lörinc, E., Fernebro, E., Nilbert, M., Sjölander, A., Magnusson, C., Mezhybovska, M., Lörinc, E., Fernebro, E., Nilbert, M., & Sjölander, A. (2010). Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. European Journal of Cancer, 46(4), 826-35. https://doi.org/10.1016/j.ejca.2009.12.022, https://doi.org/10.1016/j.ejca.2009.12.022

Vancouver

Magnusson C, Mezhybovska M, Lörinc E, Fernebro E, Nilbert M, Sjölander A et al. Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. European Journal of Cancer. 2010;46(4):826-35. https://doi.org/10.1016/j.ejca.2009.12.022, https://doi.org/10.1016/j.ejca.2009.12.022

Author

Magnusson, Cecilia ; Mezhybovska, Maryna ; Lörinc, Ester ; Fernebro, Eva ; Nilbert, Mef ; Sjölander, Anita ; Magnusson, Cecilia ; Mezhybovska, Maryna ; Lörinc, Ester ; Fernebro, Eva ; Nilbert, Mef ; Sjölander, Anita. / Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. In: European Journal of Cancer. 2010 ; Vol. 46, No. 4. pp. 826-35.

Bibtex

@article{d1b3c39d7cee4d6894bcf80dacbd10c0,
title = "Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer",
abstract = "Colorectal cancer is the third most common cancer type in the Western world. In search of new treatment possibilities, the inflammation mediators, know as cysteinyl leukotrienes (CysLTs), have been shown to regulate intestinal epithelial cell survival and proliferation via the CysLT(1)R, and cell differentiation via the CysLT(2)R. These results prompted us to investigate the significance of CysLT(1)R and CysLT(2)R expression in colorectal cancer tissue for patient survival. The CysLT(1)R, CysLT(2)R, beta-catenin and Bcl-xL protein expression levels were evaluated by immunohistochemistry in a tissue microarray of 329 colorectal patients. We found that high nuclear expression of CysLT(1)R is associated with a poor prognosis, whereas high nuclear expression of CysLT(2)R is associated with a good prognosis. We also observed that patients with colorectal tumours characterised by high CysLT(1)R but low CysLT(2)R nuclear expression had the lowest survival expectancy, whereas patients with colorectal tumours characterised by low CysLT(1)R but high CysLT(2)R nuclear expression had the best survival expectancy. Interestingly, beta-catenin as a single prognostic marker did not exhibit any prognostic value. However, in patients with tumours characterised by a high CysLT(1)R nuclear expression, an elevated beta-catenin nuclear expression had a significantly prognostic value. In conclusion these data indicate that nuclear expressions of CysLTRs are potential prognostic indicators of colorectal cancer.",
author = "Cecilia Magnusson and Maryna Mezhybovska and Ester L{\~A}¶rinc and Eva Fernebro and Mef Nilbert and Anita Sj{\~A}¶lander and Cecilia Magnusson and Maryna Mezhybovska and Ester L{\"o}rinc and Eva Fernebro and Mef Nilbert and Anita Sj{\"o}lander",
note = "Copyright 2009 Elsevier Ltd. All rights reserved.",
year = "2010",
doi = "10.1016/j.ejca.2009.12.022",
language = "English",
volume = "46",
pages = "826--35",
journal = "European Journal of Cancer, Supplement",
issn = "0959-8049",
publisher = "Pergamon",
number = "4",

}

RIS

TY - JOUR

T1 - Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer

AU - Magnusson, Cecilia

AU - Mezhybovska, Maryna

AU - Lörinc, Ester

AU - Fernebro, Eva

AU - Nilbert, Mef

AU - Sjölander, Anita

AU - Magnusson, Cecilia

AU - Mezhybovska, Maryna

AU - Lörinc, Ester

AU - Fernebro, Eva

AU - Nilbert, Mef

AU - Sjölander, Anita

N1 - Copyright 2009 Elsevier Ltd. All rights reserved.

PY - 2010

Y1 - 2010

N2 - Colorectal cancer is the third most common cancer type in the Western world. In search of new treatment possibilities, the inflammation mediators, know as cysteinyl leukotrienes (CysLTs), have been shown to regulate intestinal epithelial cell survival and proliferation via the CysLT(1)R, and cell differentiation via the CysLT(2)R. These results prompted us to investigate the significance of CysLT(1)R and CysLT(2)R expression in colorectal cancer tissue for patient survival. The CysLT(1)R, CysLT(2)R, beta-catenin and Bcl-xL protein expression levels were evaluated by immunohistochemistry in a tissue microarray of 329 colorectal patients. We found that high nuclear expression of CysLT(1)R is associated with a poor prognosis, whereas high nuclear expression of CysLT(2)R is associated with a good prognosis. We also observed that patients with colorectal tumours characterised by high CysLT(1)R but low CysLT(2)R nuclear expression had the lowest survival expectancy, whereas patients with colorectal tumours characterised by low CysLT(1)R but high CysLT(2)R nuclear expression had the best survival expectancy. Interestingly, beta-catenin as a single prognostic marker did not exhibit any prognostic value. However, in patients with tumours characterised by a high CysLT(1)R nuclear expression, an elevated beta-catenin nuclear expression had a significantly prognostic value. In conclusion these data indicate that nuclear expressions of CysLTRs are potential prognostic indicators of colorectal cancer.

AB - Colorectal cancer is the third most common cancer type in the Western world. In search of new treatment possibilities, the inflammation mediators, know as cysteinyl leukotrienes (CysLTs), have been shown to regulate intestinal epithelial cell survival and proliferation via the CysLT(1)R, and cell differentiation via the CysLT(2)R. These results prompted us to investigate the significance of CysLT(1)R and CysLT(2)R expression in colorectal cancer tissue for patient survival. The CysLT(1)R, CysLT(2)R, beta-catenin and Bcl-xL protein expression levels were evaluated by immunohistochemistry in a tissue microarray of 329 colorectal patients. We found that high nuclear expression of CysLT(1)R is associated with a poor prognosis, whereas high nuclear expression of CysLT(2)R is associated with a good prognosis. We also observed that patients with colorectal tumours characterised by high CysLT(1)R but low CysLT(2)R nuclear expression had the lowest survival expectancy, whereas patients with colorectal tumours characterised by low CysLT(1)R but high CysLT(2)R nuclear expression had the best survival expectancy. Interestingly, beta-catenin as a single prognostic marker did not exhibit any prognostic value. However, in patients with tumours characterised by a high CysLT(1)R nuclear expression, an elevated beta-catenin nuclear expression had a significantly prognostic value. In conclusion these data indicate that nuclear expressions of CysLTRs are potential prognostic indicators of colorectal cancer.

U2 - 10.1016/j.ejca.2009.12.022

DO - 10.1016/j.ejca.2009.12.022

M3 - Journal article

C2 - 20064706

VL - 46

SP - 826

EP - 835

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 0959-8049

IS - 4

ER -

ID: 34375391